OVERVIEW

Discover the future of diabetes care.
Beta cell research is evolving rapidly—and the implications for clinical practice are closer than ever. Join the American Diabetes Association® for a thought-provoking webinar that distills the most important advances in beta cell science presented at the 85th Scientific Sessions. 

An expert panel will highlight the most up-to-date research and translate breakthrough findings, exploring: 

• The current state of beta cell biology  
• Clinical readiness and pipeline timing for new interventions 
• How emerging evidence could reshape care and research priorities 

Why attend? 
This session goes beyond the data to ask what’s next: how soon might these discoveries reach patients, and what do clinicians need to know now to prepare?

Don’t miss this opportunity to stay at the forefront of diabetes science and practice.

LEARNING OBJECTIVES

• Identify research highlights from the ADA 85th Scientific Sessions related to beta cell function.
• Relate how emerging evidence on beta cell function will impact clinical care in the future. 
• Apply insights on beta cell function to inform future patient care decisions. 

BENEFITS

This is a non-CE webinar. Learners will benefit from direct access to leading experts and emerging insights on beta cell function from the ADA’s 85th Scientific Sessions.

EXPIRATION DATE

November 4, 2026

Michael R. Rickels, MD., MS

Professor of Medicine 

University of Pennsylvania Perelman School of Medicine 

Philadelphia, PA 

Dr. Rickels is the Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases at the University of

Pennsylvania Perelman School of Medicine where Dr. Rickels serves as Director of Clinical Science in the Division of Endocrinology, Diabetes and Metabolism, Director for Translational Research in the Institute for Diabetes, Obesity & Metabolism, and Medical Director for the Pancreatic Islet Cell Transplant Program. Dr. Rickels conducts patient‐oriented diabetes research that is focused on the physiology of islet function and replacement and glucose counterregulation in defense against hypoglycemia in type 1 diabetes and pancreatogenic forms of diabetes such as cystic fibrosis‐related diabetes. This work has been continuously funded by the National Institutes of Health. Dr. Rickels is an elected member of the Association of American Physicians and presently serves as Treasurer for the International Pancreas and Islet Transplant Association, and as Associate Editor for the American Diabetes Association’s clinical research journal Diabetes Care, where he co‐hosts the podcast Diabetes Care “On Air”. 

Kimber Simmons, MD, MS

Associate Professor of Pediatrics 

Barbara Davis Center for Diabetes 

University of Colorado School of Medicine 

Aurora, CO 

Dr. Simmons directs the Barbara Davis Center’s Early Type 1 Diabetes and Immunotherapy Program, implementing teplizumab in clinical practice and providing care for individuals in early T1D. She leads Ask the EXPERTS, a national program guiding providers and families in interpreting and managing screening results. As principal investigator for multiple prevention and new-onset trials, her research focuses on advancing immunotherapies to preserve β-cell function and ultimately prevent type 1 diabetes.

E. Danielle Dean, PhD

Assistant Professor of Medicine and Molecular Physiology and Biophysics

Vanderbilt University Medical Center 

Nashville, TN 

Dr. Danielle Dean is an Assistant Professor of Medicine and Molecular Physiology and Biophysics at Vanderbilt University School of Medicine. She is also the Chair of the ADA's Islet Biology Interest Group. Her research is focused on understanding how individual islet endocrine cells metabolize nutrients to coordinated hormone secretion and maintain endocrine cell mass.

Holger Russ, PhD

Associate Professor 

UF Diabetes Institute 

Department of Pharmacology & Therapeutics at the University of Florida College of Medicine 

Gainesville, FL 

The emphasis of Dr. Russ`s research is on understanding the underlying molecular and cellular mechanisms resulting in autoimmune type 1 diabetes (T1D) in humans, with a focus on immune tolerance mechanisms of the insulin-producing beta cells. During his career, Dr. Russ successfully worked on different aspects of T1D, which led to several original and important contributions to the fields of beta-, thymus-, and stem cell- biology.
Dr. Russ has published more than 60 manuscripts in prominent science journals, holds several patents in the regenerative medicine space, and is a scientific co-founder of Tolerance Bio.

This activity is supported in part by Sanofi. 

Note: You do not need to be an ADA professional member to access our free continuing education programs. Simply create a free account and start exploring 70+ free CE courses. Login to get started!